Page 61 - journal_12-1_Full

Journal of Thai Traditional & Alternative Medicine Vol. 12 No. 1 January-April 2014 53

§à“‡©≈’ˬ∑’Ë«—¥‰¥â ·≈â«π”‰ª§”π«≥μ“¡ ¡°“√ °√¡«‘∑¬“»“ μ√å°“√·æ∑¬å ‚¥¬∑¥ Õ∫°“√¬—∫¬—Èß
°“√§”π«≥ ‡™◊ÈÕ‡Õ™‰Õ«’ ¥â«¬«‘∏’ Immunofluorescence Assay

π”§à“‡©≈’ˬ∑’ˉ¥â‰ª§”π«≥À“§à“§«“¡‡¢â¡¢âπ∑’Ë À√◊Õ HIV-1 p24 antigen ELISA detection
“¡“√∂¬—∫¬—ÈßÕπÿ¡Ÿ≈¥’æ’æ’‡Õ™ ¥—ßπ’È ‡´≈≈å∑’Ë„™â„π°“√∑¥ Õ∫‡™◊ÈÕ‡Õ™‰Õ«’ §◊Õ MT4 cells
Radical scavenging activity (%) ´÷Ë߇ªìπ HTLV-1 carrying adult T-cell leukemia

= {(OD control (OD sample )/OD control } × 100 cell line ·≈–‡´≈≈å∑’Ë„™â„π‡μ√’¬¡‰«√— §◊Õ MOLT-4
OD control = §à“°“√¥Ÿ¥°≈◊π· ߇©≈’ˬ¢Õß cells ´÷Ë߇ªìπ acute lymphocytic leukemia-de-
“√≈–≈“¬§«∫§ÿ¡ rives HTLV-1 negative T-cell line «‘∏’°“√

OD sample = §à“°“√¥Ÿ¥°≈◊π· ߇©≈’ˬ¢Õß ∑¥ Õ∫∑”‚¥¬‡®◊Õ®“ß “√ °—¥πÈ”‚¥¬„™â§«“¡‡¢â¡
“√≈–≈“¬μ—«Õ¬à“ßÀ√◊Õ “√≈–≈“¬§«∫§ÿ¡∫«° ¢âπ¢Õßμ—«Õ¬à“ß∑’ˉ¡à‡ªìπæ‘…μàÕ‡´≈≈å (§«“¡‡¢â¡¢âπ
π”¢âÕ¡Ÿ≈∑’ˉ¥â‰ª √â“ß°√“ø∑’Ë¡’·°π Y · ¥ß ¢Õß “√ °—¥∑’Ë¡’§à“√âÕ¬≈–¢Õ߇´≈≈å∑’Ë≈¥‰ª®“°‡´≈≈å

ƒ∑∏‘Ϭ—∫¬—ÈßÕπÿ¡Ÿ≈Õ‘ √–∑’Ë¡’Àπ૬‡ªìπ√âÕ¬≈– [Radical §«∫§ÿ¡πâÕ¬°«à“ 10%) º ¡°—∫‰«√— ‡Õ™‰Õ«’∑’Ë¡’§à“
4
scavenging activity, %] ·≈–·°π X · ¥ß§à“ HIV infectivity titer > 1 × 10 TCID /
50
§«“¡‡¢â¡¢âπ‡ªìπ≈ÁÕ§ (Log C, ‰¡‚§√≈‘μ√/¡‘≈≈‘≈‘μ√ ¡‘≈≈‘≈‘μ√ ´÷Ëßπ”¡“‡®◊Õ®“ß 10 ‡∑à“¥â«¬πÈ”‡≈’Ȭ߇´≈≈å

”À√—∫πÈ”¡—πÀÕ¡√–‡À¬À√◊Õ ‰¡‚§√°√—¡/¡‘≈≈‘≈‘μ√ ∑’Ë¡’ 20% FBS ‚¥¬º ¡ “√ °—¥ 100 ‰¡‚§√≈‘μ√
”À√—∫ “√ °—¥πÈ”) §”π«≥À“§à“§«“¡‡¢â¡¢âπ¢Õß °—∫‰«√— ·μà≈–§«“¡‡®◊Õ®“ߢÕ߉«√— 100 ‰¡‚§√≈‘μ√
“√≈–≈“¬μ—«Õ¬à“ß∑’ˬ—∫¬—ÈßÕπÿ¡Ÿ≈Õ‘ √–¥’æ’æ’‡Õ™∑’Ë ∑’Ë‡μ‘¡‰«â„π∂“¥ 96 À≈ÿ¡ §«“¡‡®◊Õ®“ß≈– 4 À≈ÿ¡
5
√âÕ¬≈– 50 (Log IC ) ‚¥¬„™â‚ª√·°√¡ª√‘´÷¡ (prism) ¢≥–‡¥’¬«°—πº ¡‡´≈≈å‡≈’È¬ß MT-4 (1 × 10 ‡´≈≈å/
50
°“√∑¥ Õ∫ƒ∑∏‘Ïμâ“πÕπÿ¡Ÿ≈Õ‘ √–‡™‘ߧÿ≥¿“æ¥â«¬«‘∏’ ¡‘≈≈‘≈‘μ√) °—∫πÈ”¬“ “√ °—¥ ¡ÿπ‰æ√„πÀ≈Õ¥
‚§√¡“‚∑°√“øﺑ«∫“ß ∑”‚¥¬π”πÈ”¡—πÀÕ¡√–‡À¬‰ª ∑¥ Õ∫¥â«¬ ·≈â«π”∂“¥ 96 À≈ÿ¡·≈–À≈Õ¥

∑¥ Õ∫¥â«¬«‘∏’«‘‡§√“–À凙àπ‡¥’¬«°—∫¢âÕ (2) ·μàπ” ∑¥ Õ∫‰ªÕ∫∑’ËÕÿ≥À¿Ÿ¡‘ 37 Õß»“‡´≈‡´’¬ , 5%
‰ªμ√«® Õ∫‚¥¬°“√æàπ¥â«¬πÈ”¬“¥’æ’æ’‡Õ™ ‚¥¬„™â §“√å∫Õπ‰¥ÕÕ°‰´¥å π“π 1 ™—Ë«‚¡ß ®“°π—Èπ‡μ‘¡‡´≈≈å
§«“¡‡¢â¡¢âπ 0.2 ‚¡≈“√å ∑‘Èß„Àâ·Àâß∑’ËÕÿ≥À¿Ÿ¡‘ÀâÕß ·≈â« 50 ‰¡‚§√≈‘μ√∑’˺ ¡°—∫ “√ °—¥ ¡ÿπ‰æ√≈߉ª∑ÿ°
𔉪μ√«® Õ∫¥â«¬°“√¥Ÿ¿“¬„μâ· ß¡Õ߇ÀÁπ‰¥â (vis- À≈ÿ¡ 𔉪‡≈’Ȭß∑’ËÕÿ≥À¿Ÿ¡‘ 37 Õß»“‡´≈‡´’¬ , 5%

ible light) —߇°μº≈¿“¬„π 30 π“∑’ ´÷ËßÀ“°¡’ §“√å∫Õπ‰¥ÕÕ°‰´¥å π“π 5 «—π ·≈â«„π‡´≈≈å„π
Õߧåª√–°Õ∫∑“߇§¡’∑’ˬ—∫¬—ÈßÕπÿ¡Ÿ≈¥’æ’æ’‡Õ™ ®–æ∫«à“ ·μà≈–À≈ÿ¡¡“∑¥ Õ∫À“§à“ HIV antigen

‡°‘¥®ÿ¥‰¡à¡’ ’∫πæ◊Èπ ’¡à«ß ¥â«¬«‘∏’ Immunofluorescence Assay §”π«≥
3. °“√∑¥ Õ∫ƒ∑∏‘Ϭ—∫¬—È߇™◊ÈÕ‡Õ™‰Õ«’ (Anti- À“ª√‘¡“≥¢Õ߉«√— ¡’§à“‡ªìπ TCID /¡‘≈≈‘≈‘μ√
50
41
Human Immunodeficiency Virus, HIV) ‡ª√’¬∫‡∑’¬∫°—∫ª√‘¡“≥‰«√— ∑’˺ ¡°—∫‡´≈≈å·μà‰¡à¡’
μ—«Õ¬à“ß “√ °—¥πÈ”∂Ÿ° à߉ª∑¥ Õ∫ƒ∑∏‘Ï “√ °—¥ ¡ÿπ‰æ√ (virus control) ·≈–§”π«≥

¬—∫¬—È߇ե å∑’ËΩÉ“¬ªØ‘∫—μ‘°“√μâ“π‡™◊ÈÕÕ—πμ√“¬ Ÿß·≈– ª√‘¡“≥‰«√— ∑’Ë≈¥≈ß®“° virus control (%reduc-
¿Ÿ¡‘§ÿâ¡°—π«‘∑¬“ ∂“∫—π«‘®—¬«‘∑¬“»“ μ√å “∏“√≥ ÿ¢ tion of HIV infectivity) “√ °—¥ ¡ÿπ‰æ√∑’Ë¡’